



Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
AMG-Studien										
Mamma-Ca	x	x			ADAPTcycle EudraCT Number 2018-003749-40	Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk, HR+/HER2- early breast cancer (ADAPTcycle)	x			
Mamma-Ca		x			SASCIA EudraCT Number 2019-004100-35	Phase III postneoadjuvant study evaluating Sacituzumab Govitecan , an Antibody Drug Conjugate in primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment - SASCIA	x			x
Mamma-Ca				x	SERENA-6 EudraCT Number 2021-000546-17	A Phase III, Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitor (Palbociclib or Abemaciclib) vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor A ctDNA Guided Early Switch Study	x			
Mamma-Ca		x			DESTINY-Breast05 GBG103 EudraCT Number	A phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in subjects with high-risk HER2-positive primary breast cancer who have residual invasive disease in breast or axillary lymph nodes following neoadjuvant therapy (DESTINY-Breast05)		x	x	
Mamma-Ca				x	ASCENT-3 GS-US-592-6238 EudraCT Number 2021-005742-14	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1				x
Mamma-Ca				x	ASCENT-4 GS-US-592-6173 EudraCT Number 2021-005743-79	A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1				x



Indikation	Adjuvant / Preventiv / Palliativ				Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
	Neo-Adjuvant	Adjuvant	Preventiv	Palliativ						
Mamma-Ca					Reko Hamor	Prospektive Kohortenstudie zur Erfassung der Lebensqualität, des chirurgischen Outcomes und perioperativer Komplikationen nach implantatbasierter Brustrekonstruktion				
		Primär	Metastasiert							
Ovar-Ca			x		AGO-OVAR 2.29 EutraCT Number 2017-000202-37	Atezolizumab in Kombination mit Bevacizumab und Che-motherapie versus Bevacizumab und Chemotherapie in re-zidivierendem Ovarialkarzinom – eine randomisierte Phase III Studie				
Ovar-Ca			x		FraStrROC	Development and prospective validation of a Frailty Score for chemotherapy associated side effects in Relapsed Ovarian Cancer				
Ovar-Ca			x		MIROVA AGO-OVAR 2.34 EudraCT Number 2018-004207-39	A randomized phase II trial of Mirvetuximab soravtansine (IMGN853) , in folate receptor alpha (FR α) high recurrent ovarian cancer eligible for platinum-based chemotherapy. (Protocol ID: AGO-OVAR 2.34).				
Ovar-Ca		x			AGO-OVAR 28 / ENGOT-ov57 EudraCT Number 2021-001271-16	Niraparib vs Niraparib in combination with Bevacizumab in patients with carboplatinum-taxane based chemotherapy in advanced ovarian cancer (A multicentre randomised phase III trial) (Protocol-code: AGO-OVAR 28 / ENGOT-ov57)				
Sonstige Studien										



Indikation	Neo-Adjuvant	Adjuvant	Preventiv	Paliativ	Kurztitel	Vollständiger Titel	ER+ HER2-	ER+ HER+	ER- HER2+	TNBC
Mamma- Ca und Schwangerschaft					GBG 29 BCP	Prospektive Registerstudie zur Diagnostik und Therapie des Mamma-karzinoms in der Schwangerschaft Pat. mit histologisch gesichertem Mammakarzinom und Schwangerschaft	x	x	x	x
Mamma-Ca				x	GBG79 BrainMet	Brain Metastases in Breast Cancer Network Germany (BMBC) Meeting a clinical need for the improvement of patient outcome	x	x	x	x
Mamma-Ca beim Mann					Register Magdeburg	Mammakarzinom des Mannes. Eine prospektive Registerstudie der Universitätsfrauenklinik Magdeburg in Zusammenarbeit mit den klinischen Krebsregistern zur Diagnostik und Therapie des Mammakarzinoms des Mannes	x	x	x	x
alle gyn. Tumorpatienten					Psychonkologische Studie von ONKOTRAKT	Epidemiologische Untersuchung zur Belastung von Krebspatienten (Verbesserung der Erkennung des psychoonkologischen Betreuungsbedarfs bei Krebskranken)				
Gyn-Sarkome					REGSA	Deutsche prospektive Registerstudie zur Erfassung der Behandlung von gynäkologischen Sarkomen in der klinischen Routine				